Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody Discovery Kits. The Multicell Assay ...

Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March.

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...